EHA 2021 - Annual Congress of the European Hematology Association (Virtual Meeting)
Jun 09 - Jun 17, 2021 | ViennaAustria
LARVOL is not affiliated with Annual Congress of the European Hematology Association (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 398 abstracts linked to Trials
[VIRTUAL] FIRST INTERIM ANALYSIS OF ALPINE STUDY: RESULTS OF A PHASE 3 RANDOMIZED STUDY OF ZANUBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
[VIRTUAL] OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY
[VIRTUAL] KTE-X19 VERSUS STANDARD OF CARE FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PREVIOUSLY TREATED WITH BRUTON TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM EUROPE
[VIRTUAL] A COMPARISON OF CLINICAL OUTCOMES FROM ZUMA-5 (AXICABTAGENE CILOLEUCEL) AND THE INTERNATIONAL SCHOLAR-5 EXTERNAL CONTROL COHORT IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
[VIRTUAL] FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY
[VIRTUAL] EARLY INTENSIVE CONSOLIDATION WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
[VIRTUAL] IBRUTINIB TREATMENT IN THE FIRST-LINE SETTING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: UP TO 7 YEARS OF FOLLOW-UP IN THE RESONATE-2 STUDY
[VIRTUAL] FIRST RESULTS OF A HEAD-TO-HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA
[VIRTUAL] PRIMARY ANALYSIS OF THE FIXED-DURATION COHORT FROM THE PHASE 2 CAPTIVATE STUDY OF FIRST-LINE IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
[VIRTUAL] OUTCOMES IN ZUMA-5 WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WHO HAD THE HIGH-RISK FEATURE OF EARLY PROGRESSION AFTER FIRST CHEMOIMMUNOTHERAPY
[VIRTUAL] MOSUNETUZUMAB (MOSUN) MONOTHERAPY FOR ELDERLY/UNFIT PATIENTS (PTS) WITH FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) CONTINUES TO SHOW PROMISING SAFETY AND EFFICACY WITH DURABLE COMPLETE RESPONSES
[VIRTUAL] TOLERABILITY AND EFFICACY OF THE COMBINATION OF PI3KΔ INHIBITOR ZANDELISIB (ME-401) AND BTK INHIBITOR ZANUBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) B-CELL MALIGNANCIES: INITIAL RESULTS
[VIRTUAL] SAFETY AND EFFICACY OF CD37-TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND OTHER NON-HODGKIN’S B-CELL LYMPHOMAS – A PHASE 2 STUDY
[VIRTUAL] NAVITOCLAX AND RUXOLITINIB FOR PATIENTS WITH MYELOFIBROSIS AND JAK INHIBITOR EXPERIENCE: RESPONSE DURATION IN PHASE 2 STUDY
[VIRTUAL] ACTIVATION OF DISTINCT INFLAMMATORY PATHWAYS IS DRIVEN BY GENETICS IN MDS